Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species

3 Feb 2009

Abstract excerpt

The fluconazole MIC distributions for Candida glabrata from testing 34 different clinical isolates and performing 51 tests on a single isolate mirrored each other. Since what is perceived as biological variation in isolates without resistance mechanisms is mainly methodological variation, breakpoints which divide this distribution not only lack a sound biological basis but also result in poor reproducibility of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal resistance and susceptibility
Share to Fungal Infections and Studies
Share to Probiotics and Fermented Foods

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19188378
DOI: 10.1128/aac.01624-08

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target SpeciesPMID 19188378Read ↗

Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values—laboratory and clinical utilitySemantic proximity Read ↗

Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods.Semantic proximity Read ↗

Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Semantic proximity Read ↗

Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsSemantic proximity Read ↗

Correlation of MIC with Outcome for <i>Candida</i> Species Tested against Voriconazole: Analysis and Proposal for Interpretive BreakpointsSemantic proximity Read ↗

Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year periodSemantic proximity Read ↗

Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?Semantic proximity Read ↗

Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.